Human COMP/Thrombospondin-5 Antibody

Catalog #: MAB31341 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB31341
MAB31341-SP

Detection of Human COMP/Thrombospondin‑5 by Western Blot.

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human COMP/Thrombospondin-5 Antibody Summary

Species Reactivity

Human

Specificity

Detects human COMP in Western blots.

Source

Monoclonal Mouse IgG₁ Clone # 2127-F5

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Bacteria-derived recombinant human COMP

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Recommended Concentration

Sample

Western Blot

2 µg/mL

See below

Immunoprecipitation

25 µg/mL

Conditioned cell culture medium spiked with Recombinant Human COMP/Thrombospondin‑5 (Catalog # 3134-CP), see our available Western blot detection antibodies

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human COMP/Thrombospondin‑5 by Western Blot. Western blot shows lysates of human cartilage tissue. PVDF membrane was probed with 2 µg/mL of Human COMP/Thrombospondin-5 Monoclonal Antibody (Catalog # MAB31341) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: COMP/Thrombospondin-5

Cartilage Oligomeric Matrix Protein (COMP), also known as Thrombospondin-5, is a 110 kDa multidomain calcium binding protein that associates with other extracellular matrix molecules. Thrombospondin-1 and -2 constitute subgroup A and form homotrimers, whereas Thrombospondin-3, -4, and COMP constitute subgroup B and form homopentamers (1-4). The human COMP cDNA encodes a 757 amino acid (aa) precursor that includes a 20 aa signal sequence followed by a non-collagenous coiled-coil domain, four EGF-like repeats, seven TSP type-3 repeats, and a globular TSP C-terminal domain (5). Human COMP shares 86-93% aa sequence identity with rat, mouse, equine, bovine, and canine COMP. Within the TSP type-3 repeats and TSP C-terminal domain, human COMP shares 60%, 61%, 74%, and 80% aa sequence identity with human Thrombospondin-1, -2, -3, and -4, respectively. The coiled coil domain mediates the association of COMP into disulfide-linked homopentamers with a central hub and peripheral globular domains connected by flexible strands (6, 7). An axial pore is formed by the coiled coil assembly and binds vitamin D₃ which is involved in bone and cartilage metabolism (8). An RGD sequence in the third TSP type-3 repeat mediates chondrocyte attachment via Integrin alpha 5 beta 1, although when reduced and in the absence of calcium, attachment is mediated via Integrin alpha V beta 3 (9). COMP is upregulated in rheumatoid arthritis and osteoarthritis, hepatocellular carcinomas, chronic pancreatitis, and pancreatic carcinomas (10-12). Elevated circulating COMP levels are used as a biomarker for early onset of some skeletal disorders (10). Several mutations are associated with skeletal dysplasias, and the most common, a point mutation in the third TSP type-3 repeat, results in diminished calcium binding ability (13, 14).

References

Adams, J.C. and J. Lawler (2004) Int J. Biochem. Cell Biol. 36:961.
Posey, K.L. et al. (2004) Int. J. Biochem. Cell Biol. 36:1005.
Adams, J.C. (2004) Int. J. Biochem. Cell Biol. 36:1102.
Mann, H.H. et al. (2004) J. Biol. Chem. 279:25294.
Newton, G. et al. (1994) Genomics, 24:435.
DiCesare, P. et al. (1995) J. Orthopaedic Res. 13:422.
Efimov, V.P. et al. (1994) FEBS Lett. 341:54.
Ozbek, S. et al. (2002) EMBO J. 21:5960.
Chen, F.H. et al. (2005) J. Biol. Chem. 280:32655.
Wislowska, M. and B. Jablonska (2005) Clin. Rheumatol. 24:278.
Xiao, Y. et al. (2004) J. Gastroenterol. Hepatol. 19:296.
Liao, Q. et al. (2003) Scand. J. Gastroenterol. 38:207.
Kennedy, J. et al. (2005) Eur. J. Hum. Genet. 13:547.
Hou, J. et al. (2000) Cell Calcium 27:309.

Long Name

Cartilage Oligomeric Matrix Protein

Entrez Gene IDs

1311 (Human); 12845 (Mouse)

Alternate Names

cartilage oligomeric matrix protein (pseudoachondroplasia, epiphyseal dysplasia1, multiple); cartilage oligomeric matrix protein; cartilage oligomeric matrix protein(pseudoachondroplasia, epiphyseal dysplasia1, multiple); COMP; EDM1; EPD1; MED; MEDMGC131819; MGC149768; PSACH; pseudoachondroplasia (epiphyseal dysplasia 1, multiple); THBS5; Thrombospondin5; Thrombospondin-5; TSP5